Pluri Inc. Additional Paid in Capital, Common Stock
Pluri Inc. (PLUR) had Additional Paid in Capital, Common Stock of $443.84 million as of 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-09-10
- 2026-06-30: Additional Paid in Capital, Common Stock $443.84M.
- 2026-03-31: Additional Paid in Capital, Common Stock $442.39M.
- 2025-12-31: Additional Paid in Capital, Common Stock $440.84M.
- 2025-09-30: Additional Paid in Capital, Common Stock $437.55M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $443.84M 10-K · filed 2026-09-10 |
| 2026-03-31 | $442.39M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $440.84M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $437.55M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $436.21M 10-K · filed 2026-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |